Angi Martina, Kalirai Helen, Taktak Azzam, Hussain Rumana, Groenewald Carl, Damato Bertil E, Heimann Heinrich, Coupland Sarah E
Department of Clinical and Molecular Cancer Medicine, Liverpool Ocular Oncology Research Group, University of Liverpool, Liverpool, UK.
Liverpool Ocular Oncology Centre, St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK.
Br J Ophthalmol. 2017 Aug;101(8):1143-1146. doi: 10.1136/bjophthalmol-2017-310361. Epub 2017 Jun 8.
Accurate survival prognostication for patients with uveal melanoma (UM) enables effective patient counselling and permits personalised systemic surveillance for the early detection of metastases and, in high-risk patients, enrolment in any trials of systemic adjuvant therapy. The aim of this work is to determine the success of prognostic UM tumour biopsy using an improved surgical approach and optimised sample handling workflow.
Patients with UM treated by primary radiotherapy between 2011 and 2013 and who underwent a prognostic biopsy with cytology, multiplex ligation-dependent probe amplification and/or microsatellite analysis were included. The main outcomes and measures were success of cytology and genetic studies, and surgical complications.
The cohort comprised 232 patients with UM having a median age of 59 years (range, 25-82) at treatment. The median largest basal diameter was 11.4 mm (range, 4.1-20.8) and tumour height was 3.4 mm (range, 0.7-10.3). Ciliary body involvement was noted in 42 cases. Treatment consisted of Ru-106 brachytherapy in 151 cases (65%) and proton beam radiotherapy in 81 cases (35%). With improvements in surgical techniques and laboratory methods over time, cytology success increased from 92% (131/142) to 99% (89/90) and the numbers of samples with sufficient DNA for genetic testing increased from 79% (104/131) to 93% (83/89). Overall, chromosome 3 loss was noted in 64/187 (34%) cases. Surgical complications, including transient localised bleeding, vitreous haemorrhage and retinal perforation, decreased over time. Eight patients required additional surgery.
Improved surgical techniques and laboratory methods yielded successful cytology and genetic information in the majority of cases.
Analysis of data from 232 patients with uveal melanoma undergoing prognostic tumour biopsy demonstrated that improved surgical techniques and laboratory methods yielded successful cytology and genetic information in 99% and 89% of cases, respectively.
准确预测葡萄膜黑色素瘤(UM)患者的生存期有助于为患者提供有效的咨询,并允许进行个性化的全身监测,以便早期发现转移灶,对于高危患者,还能让其参与全身辅助治疗的任何试验。这项工作的目的是使用改进的手术方法和优化的样本处理流程来确定预后性UM肿瘤活检的成功率。
纳入2011年至2013年间接受原发性放疗并进行了预后性活检(包括细胞学检查、多重连接依赖探针扩增和/或微卫星分析)的UM患者。主要结局和指标为细胞学和基因研究的成功率以及手术并发症。
该队列包括232例UM患者,治疗时的中位年龄为59岁(范围25 - 82岁)。最大基底直径的中位数为11.4毫米(范围4.1 - 20.8毫米),肿瘤高度为3.4毫米(范围0.7 - 10.3毫米)。42例患者出现睫状体受累。治疗包括151例(65%)的钌 - 106近距离放疗和81例(35%)的质子束放疗。随着时间推移手术技术和实验室方法的改进,细胞学成功率从92%(131/142)提高到99%(89/90),有足够DNA用于基因检测样本的数量从79%(104/131)增加到93%(83/89)。总体而言,187例中有64例(34%)出现3号染色体缺失。手术并发症,包括短暂局部出血、玻璃体积血和视网膜穿孔,随时间减少。8例患者需要额外手术。
改进的手术技术和实验室方法在大多数病例中获得了成功的细胞学和基因信息。
对232例接受预后性肿瘤活检的葡萄膜黑色素瘤患者的数据进行分析表明,改进的手术技术和实验室方法分别在99%和89%的病例中获得了成功的细胞学和基因信息。